The use of recombinant human activated protein C (drotrecogin alpha) in solid organ transplant recipients: Case series and review of the literature

Transplant Infectious Disease

Volumn 13, Issue 6, 2011, Pages 592-597

  Funk, D J ^a   Palma Vargas, J ^b   Tuttle Newhall, J ^b   Moretti, E W ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Activated protein C; Drotrecogin alpha; Septic shock; Transplant recipients

Indexed keywords

DROTRECOGIN; HYPERTENSIVE AGENT;

ADULT; AGED; APACHE; ARTIFICIAL VENTILATION; BLEEDING; CADAVER DONOR; CLINICAL ARTICLE; FLUID RESUSCITATION; GRAFT SURVIVAL; HUMAN; INFECTION CONTROL; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MORTALITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SEPTIC SHOCK;

ADULT; AGED; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSION; MIDDLE AGED; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PROTEIN C; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 84155189170     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00636.x     Document Type: Review

References (27)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001; 29: S109-S116.
3. Bates DW, Yu DT, Black E, et al. Resource utilization among patients with sepsis syndrome. Infect Control Hosp Epidemiol 2003; 24: 62-70.
4. Kalil AC, Dakroub H, Freifeld AG. Sepsis and solid organ transplantation. Curr Drug Targets 2007; 8: 533-541.
5. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MAJr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537.
6. Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72: 128-133.
7. Esmon CT, Taylor FB, Snow TR. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 1991; 66: 160-165.
8. Stouthard JM, Levi M, Hack CE, et al. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost 1996; 76: 738-742.
9. Bernard GR, Ely EW, Wright TJ, et al. Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29: 2051-2059.
10. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
11. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680-1686.
12. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
13. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
14. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
16. Data on File. Lilly Research Laboratories. Eli Lilly Pharmaceuticals, Indianapolis, Indiana.
17. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005; 33: 2266-2277.
18. Browne E, Cressey DM, Agarwal K, Cosgrove JF. The use of drotrecogin alfa (activated) in a patient with recent orthotopic liver transplant. Anaesthesia 2007; 62: 282-285.
19. Al-Sabah S, Goldberg P, Qureshi ST. Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alpha (activated). Transpl Infect Dis 2007; 9: 233-236.
20. Daniels TL, Dummer JS, Bernard GR, Milstone AP.A case series of drotrecogin alfa (activated) in lung transplant recipients. Transplantation 2006; 81: 1739-1742.
21. Feltracco P, Bortolato A, Rizzi S, et al. Activated recombinant protein C in septic shock early after liver transplantation: a case report. Transplant Proc 2008; 40: 2070-2072.
22. Feltracco P, Rea F, Ori C. Drotrecogin alpha (activated) in septic shock after lung transplant. J Heart Lung Transplant 2008; 27: 815.
23. Grochowiecki T, Nazarewski S, Meszaros J, et al. Use of drotrecogin alpha (recombinant human activated protein C, rhAPC) in the treatment of severe sepsis induced by graft pancreatitis after simultaneous pancreas and kidney transplantation: a case report. Transplant Proc 2006; 38: 276-279.
24. Kulkarni S, Naureckas E, Cronin DC2nd. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003; 75: 899-901.
25. Berkman S, Weimert NA, Taber DJ, et al. The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series. Transpl Infect Dis 2009; 11: 269-276.
26. Pronovost PJ, Angus DC, Dorman T, Robinson KA, Dremsizov TT, Young TL. Physician staffing patterns and clinical outcomes in critically ill patients: a systematic review. JAMA 2002; 288: 2151-2162.
27. Fink MP. Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result of an acquired intrinsic derangement in cellular respiration? Crit Care Clin 2002; 18: 165-175.